Lanmar

EDIT - another genomics name that looks ready

看多
NASDAQ:EDIT   Editas Medicine, Inc.
All major gene editing stocks look like they're on the cusp of big moves higher. (See last post on NTLA)

Zoomed in on the shorter time frame we have a trigger off the 618 4hr retrace. There's some overhead supply in the 50s for shorter term targets, but this is a long term play with much higher upside.

Seeing similar in CRSP, but EDIT is showing a more significant breakout on the monthly time frame
Short term quick look at CRSP:

NTLA is the leader in the sector right now, but that could change fast. I am long all three
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。